Bluebird bio Inc (BLUE)

NASDAQ
30.48
+0.81(+2.73%)
After Hours
30.11
-0.37(-1.21%)
- Real-time Data
  • Volume:
    1,078,064
  • Bid/Ask:
    30.10/30.44
  • Day's Range:
    29.55 - 30.65

BLUE Overview

Prev. Close
29.67
Day's Range
29.55 - 30.65
Revenue
241.66M
Open
29.98
52 wk Range
24.25 - 72.5
EPS
-9.38
Volume
1,078,064
Market Cap
2.06B
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
2,284,015
P/E Ratio
-
Beta
1.74
1-Year Change
-48.58%
Shares Outstanding
67,447,548
Next Earnings Date
Aug 04, 2021
What is your sentiment on Bluebird bio Inc?
or
Market is currently closed. Voting is open during market hours.

Bluebird bio Inc News

Bluebird bio Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuyStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell

Bluebird bio Inc Company Profile

Bluebird bio Inc Company Profile

Employees
1213

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Read More
  • great news,blue will be moving up soon since they moved away from Germany 🇩🇪
    1
    • Why red ? 34 at 28 ... disgusting
      1
      • why red? forever red?
        1
        • https://endpts.com/bristol-myers-squibb-faces-1b-tax-lawsuit-after-accidental-disclosure-reveals-alleged-offshore-patents-scheme-report/
          0
          • why does it go down?
            0
            • honest answer - nobody knows
              0
          • Obviously there is a serious problem if it doesn't fly into space with such news ... Skeletons in the wardrobe or too much debt ???
            0
            • Or just big market manipulation.
              0
          • should be much higher - any bad news its -40% and good news +4%???!!!
            0
            • if it were so easy to find a correlation on the stock exchange and on pharma stocks ...
              0
          • Pre-market not picking up !!
            0
            • FDA approval with short sqeuze Blue will hit 50+ on Monday.
              2
              • I hope we will close that gap
                0
              • Now down 29$ not 50
                0
            • U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma
              0
              • Monday gaps up 40%
                0
              • Serdar Atesgap down monster -10%
                0
            • FDA approved!
              0
              • FDA approves this stock
                0
                • Up we go!
                  0
                  • 27th March, this should recover nicely
                    0
                    • There is a FDA priority approval coming for one of their trial
                      0
                    • Approved :) monday +30%
                      0
                    • ....
                      0
                  • Caiu mais. FDA não aprovou.
                    1
                    • FDA approvs
                      0
                      • Approve what?
                        1
                      • LentiGlobin
                        0
                      • Serdar Atesno i didnt they put it on hold
                        0
                    • Should i sell my stock?
                      1
                      • Sell paperhands
                        0
                      • hold
                        0
                      • Taylor Swansongo diamond hands
                        0
                    • bankrupt?
                      5
                      • 100+ by March end.
                        3
                        • 20 soom
                          7
                          • BUY. it goes to 35
                            0
                            • SOLD :( It goes to 15!!
                              5
                              • Cold outside?
                                1
                            • 20 soon
                              8
                              • This looks promising! What's the dip?
                                0
                                • why was down to much ?
                                  0
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.